Description
CJC-1295 with DAC is a modified analogue of Growth Hormone Releasing Hormone (GHRH) engineered to dramatically extend its duration of action.
Product characteristics
| Specification | Details |
| Product | CJC-1295 with DAC |
| Quantity | 2 mg per vial |
| Form | Lyophilised powder |
| Purity | ≥99.64% (HPLC tested) |
| Molecular formula: | C165H269N47O46 |
| Molecular weight | 3647.65 g/mol |
| Storage | Refrigerated at 2–8°C |
| Intended application | Laboratory and analytical research |
Quality control
Current batch: CWD2-A0612
- Internal HPLC purity: 99.64%
Further information
CJC-1295 belongs to the GHRH analogue and growth hormone signaling research class. For a broader overview of GH signaling pathways and comparative peptide mechanisms, see our Growth hormone peptides research guide and the CJC-1295 DAC vs no DAC article.
For general laboratory preparation and handling, consult our Peptide Reconstitution Guide.
Disclaimer
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.








